Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy
Start Date
5/1/2011
Completion Date
3/1/2026
Summary
The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.
Detailed Description
To collect specimens for the purpose of developing a prenatal aneuploidy test. The test will analyze circulating cell free fetal (ccff) nucleic acid from blood samples from pregnant women who have an increased risk indicator/s for fetal chromosomal aneuploidy and are undergoing invasive prenatal diagnosis by chorionic villus sampling (CVS) and/or genetic amniocentesis. The results of the ccff aneuploidy test will be compared to the chromosomal analysis obtained via CVS or genetic amniocentesis.
Eligibility Criteria
Age Range: 18 years to No maximum
Conditions
Locations
University of Alabama Birmingham
Birmingham, Alabama 35294
United States
Cedars-Sinai Medical Center
Los Angeles, California 90048
United States
Sharp-Rees Stealy Medical Group
San Diego, California 92101
United States
UCSD
San Diego, California 92121
United States
Women's Health Care Research
San Diego, California 92123
United States
Specialty Obstetrics of San Diego
San Diego, California 92130
United States
Reproductive Genetics Institute
Chicago, Illinois 60602
United States
University of Iowa Health Care
Iowa City, Iowa 52242
United States
Henry Ford Hospital
Detroit, Michigan 48202
United States
Spectrum Health
Grand Rapids, Michigan 49503
United States
The Cooper Health System
Camden, New Jersey
United States
Medical University of South Carolina
Charleston, South Carolina 29466
United States
IWK Health Centre
Halifax, Nova Scotia B3K 6R8
Canada
North York General Hospital
Toronto, Ontario
Canada